Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Skeletal system

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    85 result(s) found for: Skeletal system. Displaying page 3 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2021-002641-15 Sponsor Protocol Number: PBP-301 Start Date*: 2021-10-27
    Sponsor Name:Point BioPharma Inc.
    Full Title: SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment
    Medical condition: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001361-27 Sponsor Protocol Number: ICR-CTSU/2015/10054 Start Date*: 2016-09-21
    Sponsor Name:The Institute of Cancer Research
    Full Title: CTC-STOP: Utilising Circulating Tumour Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer.
    Medical condition: Advanced Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001198 Adenocarcinoma of the prostate metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004003-46 Sponsor Protocol Number: RealMM Start Date*: 2018-09-05
    Sponsor Name:DIPARTIMENTO DI BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE-UNIVERISITÀ DI TORINO
    Full Title: A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT...
    Medical condition: Newly diagnosed MM patients = 65 years old or ineligible for autologous stem cell transplant
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004436-21 Sponsor Protocol Number: WN42636 Start Date*: 2021-08-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH GENERALIZED MYASTH...
    Medical condition: Generalized Myasthenia Gravis (gMG)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed) NL (Completed) FR (Completed) PL (Completed) IT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-005599-33 Sponsor Protocol Number: AMSC-BDT-001 Start Date*: 2013-06-10
    Sponsor Name:Lékařská fakulta Univerzity Karlovy v Hradci Králové
    Full Title: Utilization of Autologous Multipotent Mesenchymal Stem Cells in the Management of the Large Skeletal Defects during Revision Total Hip Arthroplasty: a Prospective, Non-randomized, Open-Label Study ...
    Medical condition: Revision total hip arthroplasty.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10044088 Total hip replacement LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003131-35 Sponsor Protocol Number: AA-HPP-208 Start Date*: 2016-04-19
    Sponsor Name:Alexion Pharma GmbH
    Full Title: A Phase 2a Randomized, Multi-center, Open-Label, Pharmacokinetic, and Dose Response Study of Asfotase Alfa in Adult Patients with Pediatric-Onset Hypophosphatasia
    Medical condition: Hypophosphatasia is a rare inborn error of bone metabolism caused by inactivating mutations in the gene encoding the Tissue-nonspecific alkaline phosphatase isoenzyme. With deficiency of Tissue-no...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006704-27 Sponsor Protocol Number: Bezafibrate Start Date*: 2009-07-17
    Sponsor Name:Neuromuscular Research Unit, Copenhagen University Hospital Rigshopspitalet
    Full Title: Effect of Bezafibrate on muscle metabolism during exercise in patients with fat metabolic disorders in skeletal muscle
    Medical condition: Evaluation of the effect of Bezafibrate on muscle metabolism during exercise in patients with VLCAD and CPT II deficiency
    Disease: Version SOC Term Classification Code Term Level
    12.0 10029316 Neuromuscular disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004608-32 Sponsor Protocol Number: DYN101-C102 Start Date*: Information not available in EudraCT
    Sponsor Name:Dynacure
    Full Title: A Phase 1/2, multicenter, open-label, dose-confirmation trial to evaluate the safety and preliminary efficacy of DYN101 in subjects 2 to 17 years of age with centronuclear myopathy caused by mutati...
    Medical condition: Centronuclear myopathy (CNM), in subjects 2 to 17 years of age (all ages inclusive)caused by mutations in the myotubularin1 (MTM1) or dynamin 2 (DNM2) gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10028640 Myopathies HLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002003-33 Sponsor Protocol Number: EQ06.17.01 Start Date*: 2018-12-12
    Sponsor Name:FIDIA FARMACEUTICI S.P.A.
    Full Title: A double blind, double dummy, multicenter, randomized, placebo- and active-controlled clinical trial to evaluate effectiveness of Tricortin 1000 in patients affected by chronic low back pain
    Medical condition: Low Back Pain
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10052430 Chronic lumbago LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003471-34 Sponsor Protocol Number: REN001-202 Start Date*: 2022-04-19
    Sponsor Name:Reneo Pharma Ltd.
    Full Title: AN OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF REN001 IN SUBJECTS WITH PRIMARY MITOCHONDRIAL MYOPATHY (PMM)
    Medical condition: Primary Mitochondrial Myopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10027710 Mitochondrial myopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) BE (Completed) HU (Prematurely Ended) NL (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011883-12 Sponsor Protocol Number: I2Y-MC-GHFA(c) Start Date*: 2009-08-26
    Sponsor Name:Elli Lilly and Company
    Full Title: A Phase 2 Study for Transdermal Application of Teriparatide
    Medical condition: Treatment of osteoporosis in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019820-30 Sponsor Protocol Number: CC-4047-MM-003 Start Date*: 2011-03-31
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination with Low-Dose Dexamethasone versus High-Dose Dexamethasone in Subjects with Re...
    Medical condition: Refractory Multiple Myeloma (MM) or relapsed and refractory MM.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) GR (Completed) IT (Completed) CZ (Completed) NL (Completed) ES (Completed) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-001989-38 Sponsor Protocol Number: IMCRELA Start Date*: 2021-07-08
    Sponsor Name:Facultad de medicina y ciencias de la salud de la Universidad Católica de Valencia
    Full Title: IMPACT OF THE COMBINED TREATMENT OF THE LIPOSOMATED POLYPHENOLS CÚRCULA AND RESVERATROL® WITH DUTASTERIDE, IN THE CLINICAL IMPROVEMENT OF PATIENTS WITH ALS TREATED WITH RILUZOLE
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002432-40 Sponsor Protocol Number: 042/15 Start Date*: 2016-03-03
    Sponsor Name:ASSOCIAZIONE "LA NOSTRA FAMIGLIA" - SEZIONE SCIENTIFICA I.R.C.C.S. "E.MEDEA"
    Full Title: Safety and Efficacy of yIFN treatment in Friedreich ataxia
    Medical condition: FRDA is a progressive neurodegenerative disease inherited as recessive trait. It manifests itself usually in adolescence and affects various systems including the central and peripheral nervous sys...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10017374 Friedreich's ataxia PT
    20.0 10010331 - Congenital, familial and genetic disorders 10017374 Friedreich's ataxia PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001960-45 Sponsor Protocol Number: RC18_0206 Start Date*: 2019-04-15
    Sponsor Name:CHU of Nantes
    Full Title: An intensive program with quadruplet induction and consolidation plus tandem autologous stem cell transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients: a phase II study of the Int...
    Medical condition: Young untreated patients with multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003383-47 Sponsor Protocol Number: TAK-079-1005 Start Date*: 2020-08-12
    Sponsor Name:MILLENNIUM PHARMACEUTICALS, INC.
    Full Title: A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017903-28 Sponsor Protocol Number: HO95 Start Date*: 2010-11-04
    Sponsor Name:HOVON Foundation
    Full Title: A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide mai...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) IS (Completed) BE (Completed) DK (Completed) AT (Completed) SE (Ongoing) IT (Completed) CZ (Completed) SK (Completed) GR (Ongoing) PT (Completed) FI (Completed) HU (Ongoing) LU (Completed)
    Trial results: View results
    EudraCT Number: 2010-021868-15 Sponsor Protocol Number: 9785-CL-0222 Start Date*: 2011-07-25
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer
    Medical condition: Metastatic Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-003907-16 Sponsor Protocol Number: SPIMD-301 Start Date*: 2022-03-02
    Sponsor Name:Stealth BioTherapeutics Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects with Primary Mitochondr...
    Medical condition: Primary Mitochondrial Disease Resulting from Pathogenic Nuclear DNA Mutations (nPMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    20.0 10010331 - Congenital, familial and genetic disorders 10052635 Cytoplasmic disorders congenital HLGT
    20.0 10010331 - Congenital, familial and genetic disorders 10052637 Genetic mitochondrial abnormalities NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NO (Completed) ES (Completed) IT (Completed) NL (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000078-65 Sponsor Protocol Number: Rituximab Start Date*: 2007-01-17
    Sponsor Name:Karolinska University Hospital
    Full Title: Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
    Medical condition: Adult polymyositis or adult dermatomyositis or juvenile dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036102 Polymyositis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 10:31:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA